India’s first CAR T cell therapy, NexCAR 19, is delivering encouraging early results for a specific blood cancer. Now available at 40 hospitals, the indigenous developer ImmunoACT is scaling access and building confidence in homegrown advanced treatment. The big question: can this breakthrough meaningfully change outcomes in the fight against cancer’s toughest battles?
Swipe through stories, personalise your feed, and save articles for later — all on the app.
